[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbnScPwaKAtzl2Vk4vT6QENzX599PpGiRmHazYEgDWp4":3},{"answer":4,"createTime":5,"id":6,"options":7,"origin":12,"question":19,"related":20,"source":24,"type":25},[],"2026-05-17 19:05:32",374454853,[8,9,10,11],"AML","ALL","CML","CLL",{"count":13,"courseId":14,"courseImg":15,"courseName":16,"workId":17,"workName":18},10,"ef6456b2f56beb8696cf0a54f43be86a","https:\u002F\u002Ftihai-oss-cloud.itihey.com\u002Fimg\u002F7e2d5ad53be3d12aacc56ee37db405b7.jpg","国际名校公开课","work_53247655","第七讲 急性髓系白血病及其治疗简介","急性髓系白血病英文缩写是( )",[21,26,35,44,53,63,72,81,90,99],{"answer":22,"createTime":5,"id":6,"options":23,"question":19,"source":24,"type":25},[],[8,9,10,11],"v1",0,{"answer":27,"createTime":5,"id":28,"options":29,"question":34,"source":24,"type":25},[],374454854,[30,31,32,33],"骨髓原始细胞比例","骨髓细胞的分化程度","化学染色","遗传突变","下面不属于急性髓系白血病FAB分型的依据是( )",{"answer":36,"createTime":5,"id":37,"options":38,"question":43,"source":24,"type":25},[],374454855,[39,40,41,42],"M1","M2","M3","M4","上海方案里利用三氧化二砷和全反式维甲酸治疗的AML类型属于那种( )",{"answer":45,"createTime":5,"id":46,"options":47,"question":52,"source":24,"type":25},[],374454856,[48,49,50,51],"影响mRNA成熟过程中的正常剪切与拼接","核定位信号突变,导致蛋白锚定于细胞质,从而影响其正常的生理功能","影响姐妹染色单体的粘连","影响DNA损伤的正常修复","NPM1突变导致AML的机制主要为( )",{"answer":54,"createTime":5,"id":55,"options":56,"question":61,"source":24,"type":62},[],374454857,[57,58,59,60],"ITD(内部串联重复)的插入是FLT3的突变类型之一","AML中,FLT3二聚化受阻","TKD(酪氨酸激酶活化位点的点突变)是FLT3的突变类型之一","FLT3信号通路持续被激活","AML的分子诊断中,关于FLT3描述正确的是( )",1,{"answer":64,"createTime":5,"id":65,"options":66,"question":71,"source":24,"type":62},[],374454858,[67,68,69,70],"Midostaurin","Quizartinib","Gilteritinib","Azacitidine","下列属于FLT3抑制剂的是( )",{"answer":73,"createTime":5,"id":74,"options":75,"question":80,"source":24,"type":62},[],374454859,[76,77,78,79],"DNMT3A","IDH1","IDH2","TET","下列哪些基因在AML的分子诊断中涉及到了DNA的甲基化或去甲基化修饰( )",{"answer":82,"createTime":5,"id":83,"options":84,"question":89,"source":24,"type":62},[],374454860,[85,86,87,88],"募集组蛋白去乙酰化酶,浓缩染色质,抑制靶基因的表达","募集组蛋乙酰化酶,松散染色质,促进靶基因的表达","募集DNA甲基转移酶,抑制靶基因的表达","募集DNA甲基转移酶,促进靶基因的表达","AML1-ETO融合蛋白引发AML的的机制包括( )",{"answer":91,"createTime":5,"id":92,"options":93,"question":98,"source":24,"type":62},[],374454861,[94,95,96,97],"AML治疗分为两个阶段,分别为诱导治疗阶段和巩固治疗阶段","诱导治疗阶段常采用的治疗方式为放疗或者化疗","小分子抑制剂仅可用于出现相应分子突变的AML病人","骨髓移植可作为巩固治疗阶段的一种治疗方式","下列关于AML的治疗,说法正确的是( )",{"answer":100,"createTime":5,"id":101,"options":102,"question":107,"source":24,"type":62},[],374454862,[103,104,105,106],"Bone marrow blast <5%, and absent of extrameduallary disease","Neutrophil count>1000\u002Ful","Platelet count>100000\u002Ful","Independent of blood transfusion","AML诱导治疗取得完全缓解须达到的指标包括( )"]